NCT05725902 is a Phase 2 clinical trial of Etavopivat in Sickle Cell Disease, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT05725902?

NCT05725902 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT05725902?

Interventions in NCT05725902: Etavopivat.

What condition does NCT05725902 study?

NCT05725902 studies Sickle Cell Disease.

Is NCT05725902 still recruiting?

NCT05725902 is currently completed. Last updated 8 April 2026.

Last reviewed 2026-04-08 · How we verify

NCT05725902

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease

Completed Phase 2 Last updated 8 April 2026

What this trial tests

Phase 2 trial testing Etavopivat in Sickle Cell Disease in 12 participants. Completed in 9 March 2026.

Timeline

9 March 2024

Primary endpoint
9 March 2026

9 March 2026

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	9 March 2024
Primary completion	9 March 2026
Estimated completion	9 March 2026
Sites	1 location across United States

Drugs / interventions tested

Etavopivat — full drug profile →

Conditions studied

Sickle Cell Disease — all drugs for Sickle Cell Disease →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Adults 12 to 21, any sex, with Sickle Cell Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An open-label, single arm study in patients 12 to 21 years of age with SCD to evaluate the effects of etavopivat on cerebral and muscle hemodynamics.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Current and Future Therapeutics for Treating Patients with Sickle Cell Disease.
Barak M, Hu C, Matthews A, Fortenberry YM. · · 2024 · cited 14× · PMID 38786070 · DOI 10.3390/cells13100848
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease.
Xu JZ, Vercellotti GM. · · 2023 · cited 7× · PMID 38066891 · DOI 10.1182/hematology.2023000467

Verify or expand the search:

Other trials of Etavopivat

Trials testing the same drug.

NCT07023029 — A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants · Phase 1 · completed
NCT06612268 — A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease · Phase 3 · recruiting
NCT06813924 — A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants · Phase 1 · completed
NCT06581627 — A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants · Phase 1 · completed
NCT06433661 — A Research Study of the Effect of Food on Etavopivat in Healthy Participants · Phase 1 · completed

Other recruiting trials for Sickle Cell Disease

Currently open trials in the same condition.

NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05725902 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 8 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05725902.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing